Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of remimazolam combined with nalbuphine for painless hysteroscopy
ChiCTR2200057555Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and nalbuphine in None and Procedural anxiety (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Median effective dose. Planned start May 2022; status: not yet recruiting.
02
Drugs
remimazolamnalbuphine
03
Conditions
Procedural anxiety
Beyond the preview
Go deeper on ChiCTR2200057555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057555.